Kymera Therapeutics
KYMR
100 hedge funds and large institutions have $972M invested in Kymera Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 30 reducing their positions, and 35 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 30
7.17% more ownership
Funds ownership: 88.38% → 95.55% (+7.2%)
21% less funds holding
Funds holding: 126 → 100 (-26)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
50% less capital invested
Capital invested by funds: $1.93B → $972M (-$961M)
66% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$33.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$12.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.6M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$15.6M |
| 4 |
BlackRock
New York
|
-$13.8M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$9.61M |
KYMR Hedge Fund Activity: Q2 2022 in Review
100 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2022, worth a combined $972M — down 50% from $1.93B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of KYMR and 12 opened new positions — a net loss of 23 holders — while 30 trimmed existing stakes and 42 added.
The largest buyer was Wellington Management Group, adding an estimated $42.3M. The largest seller was Fidelity Investments, cutting an estimated $36.8M.
- 100 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2022, down from 126 in Q1 2022.
- Funds reported $972M of Kymera Therapeutics stock for Q2 2022, down 50% quarter-over-quarter.
- 12 funds opened new Kymera Therapeutics positions in Q2 2022 and 35 closed out, a net change of -23 holders.
- The largest Kymera Therapeutics buyer in Q2 2022 was Wellington Management Group, an estimated $42.3M added.
- The largest Kymera Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $36.8M sold.
Based on aggregated 13F filings for Q2 2022.